|Bid||500.00 x 0|
|Ask||535.99 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (5Y Monthly)||0.26|
|PE Ratio (TTM)||153.31|
|Forward Dividend & Yield||7.83 (1.50%)|
|Ex-Dividend Date||Aug 13, 2020|
|1y Target Est||N/A|
Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo® (selpercatinib) demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal (GI) malignancies. The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021.
GlaxoSmithKline (NYSE: GSK), Vir Biotechnology (NASDAQ: VIR), and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.